Patrick Campbell

Our dermatology FDA recap for the first half of 2024 includes our top 5 approvals, 3 decisions to watch in the second half of 2024, and a podcast episode with James Del Rosso, DO

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 updates from the 84th American Diabetes Association (ADA) Scientific Sessions.

Our Cardiology Month in Review for June 2024 spotlights the pharmacotherapies making waves within the pipeline, the latest news in dyslipidemia, and updates in heart failure.

Mirum Pharmaceuticals submitted an NDA for chenodiol tablets to treat CTX based on positive phase 3 RESTORE trial results.

Jennifer Goldman, RPh, PharmD, discusses how the pharmacologic advancements in recent years have shifted discussion around lipid, and cardiovascular risk, management in diabetes.

Aquestive Therapeutics announced positive topline data from the trial on June 25, 2024.

The FDA accepted the NDA for olezarsen, an RNA-targeted medicine, in familial chylomicronemia syndrome for priority review, with a PDUFA date set for December 19, 2024.

Data on outcomes stratified according to baseline use of SGLT2 inhibitors from the FLOW trial were presented at ADA 2024.

Ralph DeFronzo, MD, discusses the results of the first phase of the CATALYST trial and how results should influence the care of patients with difficult-to-treat type 2 diabetes.

The CATALYST trial sheds light on the true prevalence of hypercortisolism among difficult-to-control type 2 diabetes, with data at ADA 2024 shedding light on adrenal abnormalities and presence among subgroups.

MOMENTUM trial data shows pemvidutide reduced body weight by 15.6%, with 78.1% fat loss, highlighting the GLP-1/Glucagon receptor agonist's ability to achieve significant weight reduction and minimal muscle loss.

An analysis of over 2.5 million patients with type 2 diabetes shows newer GLP-1 RAs are linked to lower HbA1c levels.

Halis Akturk, MD, offers an overview of the growing prevalence and dangers associated with cannabis use among patients with type 1 diabetes.

Use of LX9211 showed significant benefits for diabetic peripheral neuropathic pain in the phase 2 RELIEF-DPN 1 trial.

Details of an analysis from ADA 2024 compared matched cohorts from SURMOUNT-1 and SURMOUNT-2 to determine drivers of differences in weight loss from the trials.

Omnipod 5 improved HbA1c from 8.2% to 7.4% in 13 weeks among adults with type 2 diabetes in the SECURE-T2D trial, with a nearly 5-hour increase in time in range per day.

ADA study highlights disparities in CGM access for children with type 1 diabetes, showing delays for publicly insured and minority children.

New data from INHALE-3 at ADA 84th Scientific Sessions show inhaled insulin (Afrezza) is safe, effective for type 1 diabetes, improving glycemic control and HbA1c goals.

Atul Malhotra, MD, discusses the results of the SURMOUNT-OSA trial and how they inform clinicians on the role of tirzepatide in OSA and obesity.

An analysis of patients with acute coronary syndrome shows women receive less lipid-lowering therapy and are less likely to meet LDL-C targets than men.

Zerlasiran, a siRNA agent, significantly reduced lipoprotein(a) levels by approximately 90% at 48 weeks in high-risk cardiovascular patients, per phase 2 data from Silence Therapeutics.

New research from the SOLOST-WHF trial suggests sotagliflozin is a cost-effective treatment for diabetes patients with recent heart failure, with high cost-effectiveness probability.

Data from a new study details the apparent benefit of adding polygenic risk scores to improve cardiovascular risk stratification.

Analysis of NHANES data from 1999 to 2020 provides some evidence of diet quality improvement but highlights low rates of adults achieving ideal diet quality.

An analysis of real-world data from propensity score-matched pairs of breast cancer patients treated with anthracyclines suggests statin use was associated with an 18% reduction in all-cause mortality.

A review of nearly 500 studies spanning more than 30 years details associations between weather events and cardiovascular risk.

New research reveals that elevated lipoprotein(a) and oxidized phospholipids are independent risk factors for early-stage heart failure progression.

An analysis of survey data from more than 200 patients with atopic dermatitis details treatment satisfaction and provider trust based on racial/ethnic backgrounds of patients.

A new study suggests the AHA's PREVENT risk calculator may reduce statin use for primary prevention, affecting eligibility for millions of adults.

A post-hoc analysis of the ARCADIA program provides insight into the speed of itch relief onset observed with nemolizumab among patients with moderate-to-severe atopic dermatitis.